Is Medtronic Stock (MDT) a Buy Ahead of Earnings?

Medtronic (MDT) stock is a hot topic among traders as the medical device company is set to release its Fiscal Q4 2025 earnings report later this week. This has some investors wondering if the company’s shares are worth buying before it reports those earnings results.

First off, Wall Street expects Medtronic to report adjusted earnings per share of $1.58 alongside revenue of $8.81 billion. This would represent year-over-year increases of 8.2% for EPS and 2.6% for revenue. The company’s earnings history suggests it is likely to surpass these estimates, as it has done so in all eight of its most recent quarters.

What to Watch In the Upcoming Medtronic Earnings Report

A chief concern affecting the stock market right now is the impact of President Donald Trump’s tariffs. While the U.S. and China have agreed to temporarily lower rates, and tariff hold is in place for other countries, several industries still face heavy tariffs. This has the issue at the forefront of investors’ minds as they wait for the latest updates from companies about how they will navigate the trade war. Medtronic is no different in this regard.

Medtronic stated in April that it was monitoring tariffs and would “continue to assess potential impacts to the company and implement mitigations if necessary.” Investors will likely learn more about these plans during its upcoming earnings report and conference call.

MDT stock was up 0.09% on Monday morning and is up 9.17% year-to-date.

Is MDT Stock a Buy, Sell, or Hold?

Turning to Wall Street, the analysts’ consensus rating for Medtronic is Moderate Buy, based on seven Buy and seven Hold ratings over the last three months. With that comes an average MDT stock price target of $96.38, representing a potential 11.37% upside for the shares.

See more MDT stock analyst ratings